Angiotech partner announces 30-day safety data from its TAXUS V drug-eluting stent clinical trial
02 Oktober 2004 - 12:15AM
PR Newswire (US)
Angiotech partner announces 30-day safety data from its TAXUS V
drug-eluting stent clinical trial VANCOUVER, BC and WASHINGTON, DC,
Oct. 1 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) corporate partner, Boston
Scientific ("Boston"), today announced 30-day safety data from its
TAXUS V clinical trial. The trial is assessing the slow-release
formulation of the TAXUS(TM) Express2(TM) paclitaxel-eluting stent
system in 1,172 patients at 66 sites in the U.S. TAXUS V expands on
the TAXUS IV pivotal trial by studying a higher-risk patient
population, including patients with small vessels, large vessels
and long lesions requiring multiple overlapping stents. Boston made
the announcement at the annual Transcatheter Cardiovascular
Therapeutics symposium in Washington, D.C. The TAXUS V trial -
which includes the use of multiple stents as well as single stents
- is designed to assess the safety and efficacy of a paclitaxel-
eluting coronary stent in reducing restenosis in de novo lesions 10
- 46 mm in length and 2.25 - 4.0 mm in diameter. It has a primary
endpoint of nine-month target vessel revascularization (TVR). The
results support early safety, as demonstrated by a low overall MACE
(Major Adverse Cardiac Events) rate of 4.4 percent at 30 days,
which is consistent with results from previous TAXUS clinical
trials. Thirty-day MACE was 3.7 percent in Group X and 5.1 percent
in Group Y (the study remains blinded through the primary endpoint
at nine months). The TVR rate was 0.7 percent in Group X and 1.2
percent in Group Y. Stent thromboses were also low, with a rate of
0.5 percent in Group X and 0.7 percent in Group Y. Boston
Scientific has acquired worldwide co-exclusive rights from
Angiotech to use paclitaxel to coat its coronary stent products and
other vascular and non-vascular products. Vancouver-based Angiotech
Pharmaceuticals, Inc., a specialty pharmaceutical company focusing
on drug-coated medical devices and biomaterials, is dedicated to
enhancing the performance of medical devices and biomaterials
through the innovative uses of pharmacotherapeutics. To find out
more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. Statements contained herein that are not
based on historical or current fact, including without limitation
statements containing the words "anticipates," "believes," "may,"
"continue," "estimate," "expects," "may" and "will" and words of
similar import, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which the Company operates;
technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified
personnel; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations; liability and
other claims asserted against the Company; and other factors
referenced in the Company's filings with the United States
Securities and Exchange Commission or the Canadian securities
regulators. Given these uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. The
Company does not assume the obligation to update any
forward-looking statements. CONTACTS: Todd Young, Angiotech
Pharmaceuticals (Analysts & Investors) (604) 221-7676 ext 6933
Rui Avelar, Angiotech Pharmaceuticals, Inc. (Analysts) (604)
221-7676 ext 6996 Eric Starkman, Starkman & Associates (Media),
(212) 252-8545 ext 12 DATASOURCE: Angiotech Pharmaceuticals, Inc.
CONTACT: Todd Young, Angiotech Pharmaceuticals (Analysts &
Investors), (604) 221-7676 ext 6933; Rui Avelar, Angiotech
Pharmaceuticals, Inc. (Analysts), (604) 221-7676 ext 6996; Eric
Starkman, Starkman & Associates (Media), (212) 252-8545 ext 12
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024